Creo Medical Group Plc

As of December 31, 2025, Creo Medical Group Plc carries a market capitalization of 4.08B, placing it among publicly traded companies globally. Its enterprise value stands at 3.25B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Creo Medical Group Plc's next confirmed earnings release is scheduled for June 2, 2027.

As of December 31, 2025, Creo Medical Group Plc has 412.47M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Creo Medical Group Plc maintains a current ratio of 3.22, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Creo Medical Group Plc's stock has gained approximately 2.27% over the past 52 weeks. The 50-day moving average sits at 11.84, while the 200-day moving average is 13.05.

As of December 31, 2025, Creo Medical Group Plc holds 1.24B in cash and equivalents against 410.00M in total debt, resulting in a net debt position of -840.00M. Total book value stands at 5.00B, with working capital of 1.62B providing operational flexibility.

Creo Medical Group Plc's most recent stock split took place on February 16, 2023 with a 857:888 split ratio.